Functional Interaction Between Trace Amine-associated Receptor 1 and Dopamine D2 Receptor

Overview

Journal Mol Pharmacol

Specialties Molecular Biology
Pharmacology

Date 2011 Jun 15

PMID 21670104

Citations 80

Authors

Stefano Espinoza

Ali Salahpour

Bernard Masri

Tatyana D Sotnikova

Mirko Messa

Larry S Barak

Marc G Caron

Raul R Gainetdinov

Affiliations

Soon will be listed here.

Abstract

The ability of dopamine receptors to interact with other receptor subtypes may provide mechanisms for modulating dopamine-related functions and behaviors. In particular, there is evidence suggesting that the trace amine-associated receptor 1 (TAAR1) affects the dopaminergic system by regulating the firing rate of dopaminergic neurons or by altering dopamine D2 receptor (D2R) responsiveness to ligands. TAAR1 is a Gα(s) protein-coupled receptor that is activated by biogenic amines, "trace amines," such as β-phenylethylamine (β-PEA) and tyramine that are normally found at low concentrations in the mammalian brain. In the present study, we investigated the biochemical mechanism of interaction between TAAR1 and D2R and the role this interaction plays in D2R-related signaling and behaviors. Using a bioluminescence resonance energy transfer biosensor for cAMP, we demonstrated that the D2R antagonists haloperidol, raclopride, and amisulpride were able to enhance selectively a TAAR1-mediated β-PEA increase of cAMP. Moreover, TAAR1 and D2R were able to form heterodimers when coexpressed in human embryonic kidney 293 cells, and this direct interaction was disrupted in the presence of haloperidol. In addition, in mice lacking TAAR1, haloperidol-induced striatal c-Fos expression and catalepsy were significantly reduced. Taken together, these data suggest that TAAR1 and D2R have functional and physical interactions that could be critical for the modulation of the dopaminergic system by TAAR1 in vivo.

Citing Articles

Regulation by Trace Amine-Associated Receptor 1 (TAAR1) of Dopaminergic-GABAergic Interaction in the Striatum: Effects of the Enhancer Drug (-)BPAP.

Harsing Jr L, Szenasi G, Feher B, Miklya I Neurochem Res. 2025; 50(2):94.

PMID: 39903411 PMC: 11794408. DOI: 10.1007/s11064-025-04337-7.

Trace amine-associated receptor 1 (TAAR1): an emerging therapeutic target for neurodegenerative, neurodevelopmental, and neurotraumatic disorders.

Dalvi S, Bhatt L Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39738834 DOI: 10.1007/s00210-024-03757-6.

Unlocking the secrets of trace amine-associated receptor 1 agonists: new horizon in neuropsychiatric treatment.

Shajan B, Bastiampillai T, Hellyer S, Nair P Front Psychiatry. 2024; 15:1464550.

PMID: 39553890 PMC: 11565220. DOI: 10.3389/fpsyt.2024.1464550.

Wakefulness Induced by TAAR1 Partial Agonism in Mice Is Mediated Through Dopaminergic Neurotransmission.

Park S, Heu J, Hoener M, Kilduff T Int J Mol Sci. 2024; 25(21).

PMID: 39518904 PMC: 11547084. DOI: 10.3390/ijms252111351.

Wakefulness Induced by TAAR1 Partial Agonism is Mediated Through Dopaminergic Neurotransmission.

Park S, Heu J, Hoener M, Kilduff T bioRxiv. 2024; .

PMID: 39314371 PMC: 11419104. DOI: 10.1101/2024.09.09.612122.

References

Sotnikova T, Budygin E, Jones S, Dykstra L, Caron M, Gainetdinov R . Dopamine transporter-dependent and -independent actions of trace amine beta-phenylethylamine. J Neurochem. 2004; 91(2):362-73. DOI: 10.1111/j.1471-4159.2004.02721.x. View

Wolinsky T, Swanson C, Smith K, Zhong H, Borowsky B, Seeman P . The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav. 2007; 6(7):628-39. DOI: 10.1111/j.1601-183X.2006.00292.x. View

Lindemann L, Meyer C, Jeanneau K, Bradaia A, Ozmen L, Bluethmann H . Trace amine-associated receptor 1 modulates dopaminergic activity. J Pharmacol Exp Ther. 2007; 324(3):948-56. DOI: 10.1124/jpet.107.132647. View

Angers S, Salahpour A, Bouvier M . Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. Annu Rev Pharmacol Toxicol. 2002; 42:409-35. DOI: 10.1146/annurev.pharmtox.42.091701.082314. View

Bouvier M . Oligomerization of G-protein-coupled transmitter receptors. Nat Rev Neurosci. 2001; 2(4):274-86. DOI: 10.1038/35067575. View

Jones K, Borowsky B, Tamm J, Craig D, Durkin M, Dai M . GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2. Nature. 1999; 396(6712):674-9. DOI: 10.1038/25348. View

Grandy D . Trace amine-associated receptor 1-Family archetype or iconoclast?. Pharmacol Ther. 2007; 116(3):355-90. PMC: 2767338. DOI: 10.1016/j.pharmthera.2007.06.007. View

Sotnikova T, Zorina O, Ghisi V, Caron M, Gainetdinov R . Trace amine associated receptor 1 and movement control. Parkinsonism Relat Disord. 2008; 14 Suppl 2:S99-102. DOI: 10.1016/j.parkreldis.2008.04.006. View

Bunzow J, Sonders M, Arttamangkul S, Harrison L, Zhang G, Quigley D . Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol. 2001; 60(6):1181-8. DOI: 10.1124/mol.60.6.1181. View

10.

Salahpour A, Masri B . Experimental challenge to a 'rigorous' BRET analysis of GPCR oligomerization. Nat Methods. 2007; 4(8):599-600. DOI: 10.1038/nmeth0807-599. View

11.

Sotnikova T, Beaulieu J, Espinoza S, Masri B, Zhang X, Salahpour A . The dopamine metabolite 3-methoxytyramine is a neuromodulator. PLoS One. 2010; 5(10):e13452. PMC: 2956650. DOI: 10.1371/journal.pone.0013452. View

12.

Breier A, Su T, Saunders R, Carson R, Kolachana B, de Bartolomeis A . Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A. 1997; 94(6):2569-74. PMC: 20129. DOI: 10.1073/pnas.94.6.2569. View

13.

Creese I, Burt D, Snyder S . Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976; 192(4238):481-3. DOI: 10.1126/science.3854. View

14.

Violin J, DiPilato L, Yildirim N, Elston T, Zhang J, Lefkowitz R . beta2-adrenergic receptor signaling and desensitization elucidated by quantitative modeling of real time cAMP dynamics. J Biol Chem. 2007; 283(5):2949-61. DOI: 10.1074/jbc.M707009200. View

15.

Moller H . Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27(7):1101-11. DOI: 10.1016/j.pnpbp.2003.09.006. View

16.

DiPilato L, Cheng X, Zhang J . Fluorescent indicators of cAMP and Epac activation reveal differential dynamics of cAMP signaling within discrete subcellular compartments. Proc Natl Acad Sci U S A. 2004; 101(47):16513-8. PMC: 534508. DOI: 10.1073/pnas.0405973101. View

17.

Sotnikova T, Caron M, Gainetdinov R . Trace amine-associated receptors as emerging therapeutic targets. Mol Pharmacol. 2009; 76(2):229-35. PMC: 2713119. DOI: 10.1124/mol.109.055970. View

18.

Ponsioen B, Zhao J, Riedl J, Zwartkruis F, van der Krogt G, Zaccolo M . Detecting cAMP-induced Epac activation by fluorescence resonance energy transfer: Epac as a novel cAMP indicator. EMBO Rep. 2004; 5(12):1176-80. PMC: 1299185. DOI: 10.1038/sj.embor.7400290. View

19.

Baldessarini R . Trace amines and alternative neurotransmitters in the central nervous system. Biochem Pharmacol. 1978; 27(5):621-6. DOI: 10.1016/0006-2952(78)90495-1. View

20.

Beaulieu J, Gainetdinov R . The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011; 63(1):182-217. DOI: 10.1124/pr.110.002642. View